Capital Investment Counsel Inc Sells 350 Shares of Bristol-Myers Squibb (NYSE:BMY)

Capital Investment Counsel Inc lessened its stake in shares of Bristol-Myers Squibb (NYSE:BMY) by 6.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,257 shares of the biopharmaceutical company’s stock after selling 350 shares during the period. Capital Investment Counsel Inc’s holdings in Bristol-Myers Squibb were worth $270,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Eagle Wealth Strategies LLC acquired a new stake in Bristol-Myers Squibb during the fourth quarter worth about $201,000. Retirement Systems of Alabama boosted its position in shares of Bristol-Myers Squibb by 5.0% during the 4th quarter. Retirement Systems of Alabama now owns 1,365,559 shares of the biopharmaceutical company’s stock worth $70,067,000 after acquiring an additional 65,492 shares in the last quarter. Convergence Investment Partners LLC increased its stake in Bristol-Myers Squibb by 11.7% in the fourth quarter. Convergence Investment Partners LLC now owns 10,198 shares of the biopharmaceutical company’s stock valued at $523,000 after acquiring an additional 1,070 shares during the last quarter. Intellectus Partners LLC raised its position in Bristol-Myers Squibb by 1.5% during the fourth quarter. Intellectus Partners LLC now owns 37,726 shares of the biopharmaceutical company’s stock valued at $1,936,000 after purchasing an additional 574 shares in the last quarter. Finally, Financial Advisors LLC lifted its stake in Bristol-Myers Squibb by 15.1% during the fourth quarter. Financial Advisors LLC now owns 3,979 shares of the biopharmaceutical company’s stock worth $204,000 after purchasing an additional 522 shares during the last quarter. 76.41% of the stock is owned by institutional investors and hedge funds.

Bristol-Myers Squibb Trading Down 0.4 %

NYSE BMY opened at $44.65 on Tuesday. The firm has a market capitalization of $90.51 billion, a PE ratio of -14.40, a price-to-earnings-growth ratio of 15.47 and a beta of 0.39. The business’s 50-day moving average price is $50.93 and its two-hundred day moving average price is $51.02. The company has a current ratio of 1.11, a quick ratio of 0.99 and a debt-to-equity ratio of 2.99. Bristol-Myers Squibb has a 12 month low of $44.34 and a 12 month high of $69.10.

Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share for the quarter, beating analysts’ consensus estimates of ($4.53) by $0.13. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. The business had revenue of $11.87 billion during the quarter, compared to the consensus estimate of $11.45 billion. During the same quarter in the prior year, the firm posted $2.05 EPS. The company’s revenue for the quarter was up 4.7% compared to the same quarter last year. On average, analysts expect that Bristol-Myers Squibb will post 0.58 EPS for the current year.

Bristol-Myers Squibb Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, May 1st. Investors of record on Friday, April 5th will be issued a $0.60 dividend. The ex-dividend date of this dividend is Thursday, April 4th. This represents a $2.40 annualized dividend and a yield of 5.38%. Bristol-Myers Squibb’s payout ratio is -77.42%.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on BMY shares. BMO Capital Markets lowered their price target on Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating for the company in a report on Friday. Bank of America downgraded Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $68.00 to $60.00 in a research note on Wednesday, January 3rd. Redburn Atlantic downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and reduced their price target for the company from $77.00 to $54.00 in a research note on Tuesday, February 6th. Wells Fargo & Company lifted their price target on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an “equal weight” rating in a report on Thursday, April 18th. Finally, StockNews.com downgraded shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Monday, April 15th. One investment analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, Bristol-Myers Squibb presently has a consensus rating of “Hold” and a consensus target price of $60.00.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.